Drug Profile
Research programme: noscapine analogues - Cougar Biotechnology
Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Emory University
- Developer Cougar Biotechnology
- Class
- Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin modulators; Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA
- 10 Jul 2009 Cougar Biotechnology has been acquired by Johnson and Johnson
- 23 Jul 2007 This programme is still in active development